BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38696902)

  • 1. Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives.
    Jiménez-Labaig P; Rullan A; Braña I; Hernando-Calvo A; Moreno V; Doger B; Bitar G; Ap Dafydd D; Melcher A; Harrington KJ
    Cancer Treat Rev; 2024 Jun; 127():102746. PubMed ID: 38696902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
    Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
    Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck.
    Wenig BL; Werner JA; Castro DJ; Sridhar KS; Garewal HS; Kehrl W; Pluzanska A; Arndt O; Costantino PD; Mills GM; Dunphy FR; Orenberg EK; Leavitt RD
    Arch Otolaryngol Head Neck Surg; 2002 Aug; 128(8):880-5. PubMed ID: 12162764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
    Papa S; Adami A; Metoudi M; Beatson R; George MS; Achkova D; Williams E; Arif S; Reid F; Elstad M; Beckley-Hoelscher N; Douri A; Delord M; Lyne M; Shivapatham D; Fisher C; Hope A; Gooljar S; Mitra A; Gomm L; Morton C; Henley-Smith R; Thavaraj S; Santambrogio A; Andoniadou C; Allen S; Gibson V; Cook GJR; Parente-Pereira AC; Davies DM; Farzaneh F; Schurich A; Guerrero-Urbano T; Jeannon JP; Spicer J; Maher J
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37321663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers.
    Liem X; de Baère T; Vivar OI; Seiwert TY; Shen C; Pápai Z; Moreno V; Takácsi-Nagy Z; Helfferich F; Thariat J; Gooi Z; Yom SS; Bossi P; Ferris RL; Hackman TG; Le Tourneau C; Rodriguez J; Hoffmann C
    Head Neck; 2024 Jun; 46(6):1253-1262. PubMed ID: 38600434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
    Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
    Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy--phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol.
    Wollenberg B; Kastenbauer ; Mundl H; Schaumberg J; Mayer A; Andratschke M; Lang S; Pauli C; Zeidler R; Ihrler S; Löhrs ; Naujoks K; Rollston R
    Hum Gene Ther; 1999 Jan; 10(1):141-7. PubMed ID: 10022539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
    Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y
    Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
    Teknos TN; Grecula J; Agrawal A; Old MO; Ozer E; Carrau R; Kang S; Rocco J; Blakaj D; Diavolitsis V; Kumar B; Kumar P; Pan Q; Palettas M; Wei L; Baiocchi R; Savvides P
    Invest New Drugs; 2019 Aug; 37(4):702-710. PubMed ID: 30569244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of Immunotherapies in Head and Neck Cancers Using Biomaterial-Based Treatment Strategies.
    Sunga GM; Hartgerink J; Sikora AG; Young S
    Tissue Eng Part C Methods; 2023 Jun; 29(6):257-275. PubMed ID: 37183412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy of head and neck cancer : Highlights of the ASCO and ESMO annual meetings 2021].
    Theodoraki MN; Laban S; Hoffmann TK
    HNO; 2022 Apr; 70(4):271-277. PubMed ID: 35037989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.